Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* With singleton pregnancy, at least 12 weeks but not more than 31 weeks pregnant at the time of screening~* Agree not to breastfeed for the duration of the study~* Currently on a stable antiretroviral regimen for ≥ 6 months preceding the screening visit~* Documented plasma HIV-1 ribonucleic acid (RNA) levels of \< 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at the screening visit~* Have no documented or suspected resistance to FTC, Tenofovir (TFV), or integrase strand-transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R or M184V/I~* Have a normal ultrasound, completed locally prior to the Day 1 visit, with no evidence of any fetal malformation or structural abnormality affecting either fetus or placenta~* Normal maternal alfa-fetoprotein level at the screening visit~Key Exclusion Criteria:~* Have chronic hepatitis B virus (HBV)~* Have active hepatitis C virus (HCV) infection~* An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): Pregnant women participants will receive fixed dose combination (FDC) tablet of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for up to 38 weeks (from the second or third trimesters of pregnancy, depending on enrollment, through 12 weeks post-partum).
- Neonates (Type: NO_INTERVENTION): Neonates who will be born to women participants in the study will be followed from birth up to 8 weeks of age after obtaining consent from the parent or legal guardian. None of the neonates that participate in the study will be treated with the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).